Skip to content

Evaluation of the 755nm Alexandrite Laser for the Treatment of Tattoos

Evaluation of the 755nm Alexandrite Laser for the Treatment of Tattoos

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01754207
Enrollment
20
Registered
2012-12-21
Start date
2011-12-31
Completion date
2014-01-31
Last updated
2020-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tattoos

Brief summary

The purpose of this study is to collect further data on the safety and efficacy of removing unwanted non cosmetic tattoos (including recalcitrant) using the 755nm Alexandrite laser.

Interventions

755nm Alexandrite Laser

DEVICE755nm Alexandrite Laser with CAP Array

755nm Alexandrite Laser with CAP Array

Sponsors

Cynosure, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Is a healthy male or female between 18 and 85 years old. 2. Has unwanted non-cosmetic tattoo(s) and wishes to undergo laser treatments to remove them. 3. Is willing to consent to participate in the study. 4. Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits

Exclusion criteria

1. Is hypersensitive to light exposure. 2. Has active localized or systemic infection. 3. Is taking medication(s) for which sunlight is a contraindication. 4. Has a history of squamous cell carcinoma or melanoma. 5. Has a history of keloid scarring. 6. Has used oral isotretinoin (Accutane®) within 12 months of initial treatment or plans on using during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment. 7. Has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications. 8. Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period. 9. Is allergic to lidocaine, tetracaine or Xylocaine with epinephrine. 10. Has any other reason determined by the physician to be ineligible to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
Tattoo Clearance Using Photographic Evaluationup to 3 months post last treatment2D photography comparing pre and post treatment photos, where the percentage of tattoo clearance between the photos was determined by the evaluator.

Countries

United States

Participant flow

Participants by arm

ArmCount
755nm Alexandrite Laser
755nm Alexandrite Laser 755nm Alexandrite Laser: 755nm Alexandrite Laser 755nm Alexandrite Laser with CAP Array: 755nm Alexandrite Laser with CAP Array
20
Total20

Baseline characteristics

Characteristic755nm Alexandrite Laser
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
20 Participants
Fitzpatrick Skin Type
Fitzpatrick Skin Score I
4 Participants
Fitzpatrick Skin Type
Fitzpatrick Skin Score II
9 Participants
Fitzpatrick Skin Type
Fitzpatrick Skin Score III
6 Participants
Fitzpatrick Skin Type
Fitzpatrick Skin Score IV
1 Participants
Fitzpatrick Skin Type
Fitzpatrick Skin Score V
0 Participants
Fitzpatrick Skin Type
Fitzpatrick Skin Score VI
0 Participants
Race/Ethnicity, Customized
Race/Ethnicity
African American
1 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Caucasian
18 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Hispanic
1 Participants
Sex: Female, Male
Female
15 Participants
Sex: Female, Male
Male
5 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 20
other
Total, other adverse events
20 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

Tattoo Clearance Using Photographic Evaluation

2D photography comparing pre and post treatment photos, where the percentage of tattoo clearance between the photos was determined by the evaluator.

Time frame: up to 3 months post last treatment

ArmMeasureGroupValue (COUNT_OF_UNITS)
755nm Alexandrite LaserTattoo Clearance Using Photographic Evaluation>75% clearance15 Tattoos
755nm Alexandrite LaserTattoo Clearance Using Photographic Evaluation51-74% clearance6 Tattoos
755nm Alexandrite LaserTattoo Clearance Using Photographic Evaluation<25% clearance2 Tattoos

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026